Women's International Pharmacy: Prescription Process, Compounded BHRT, and How It Compares

What Is Women's International Pharmacy and Is It Legitimate?

Women's International Pharmacy is a real, licensed compounding pharmacy that has operated since 1985. It holds Pharmacy Compounding Accreditation Board (PCAB) accreditation, which requires adherence to standards set by the United States Pharmacopeia (USP) and the Accreditation Commission for Health Care. PCAB accreditation is voluntary, so holding it does signal a meaningful quality commitment above the regulatory floor.

Legitimacy as a licensed pharmacy does not mean every compounded formulation it produces carries the same evidence base as FDA-approved hormone therapies. The FDA does not review or approve individual compounded preparations for safety or efficacy before they reach patients. This distinction matters clinically.

Regulatory Framework for Compounding Pharmacies

Under the Drug Quality and Security Act of 2013, compounding pharmacies operate under either Section 503A (patient-specific compounding) or Section 503B (outsourcing facilities producing larger batches) of the Federal Food, Drug, and Cosmetic Act [1]. WIP primarily operates as a 503A pharmacy, meaning it compounds medications for individual patients based on a valid prescription.

The FDA has repeatedly stated that compounded drugs lack the premarket review of approved drugs [2]. For hormones specifically, the agency's 2020 guidance document on compounded hormone therapy noted that FDA-approved bioidentical products, including estradiol patches (e.g., Vivelle-Dot, Climara) and oral micronized progesterone (Prometrium), already exist for most clinical indications [2].

What PCAB Accreditation Actually Covers

PCAB accreditation addresses sterility testing, beyond-use dating, cleanroom standards, and quality-assurance processes. It does not validate the clinical efficacy of any specific compounded formula. A pharmacy can be PCAB-accredited and still produce a formulation for which clinical outcome data are absent. Patients and prescribers should weigh accreditation as a proxy for manufacturing quality only.

How the Prescription Intake Process Works at Women's International Pharmacy

WIP does not have in-house physicians, nurse practitioners, or other prescribers on staff. The intake process is therefore entirely prescription-driven from an external provider.

Step 1: Obtain a Prescription From Your Own Provider

A patient first consults with a licensed prescriber who writes an individualized compounding prescription. This prescriber might be a gynecologist, a functional medicine physician, a menopause-specialist internist, or a telehealth provider who operates independently of WIP. The prescription must specify the drug name, strength, dosage form, quantity, and directions.

Step 2: Send the Prescription to WIP

WIP accepts prescriptions by fax, electronic transmission, or mail. Patients can also request that their pharmacy of record forward the prescription. The pharmacy's customer-service team reviews the Rx for completeness and contacts the prescriber's office if clarification is needed.

Step 3: Compounding and Dispensing

Once verified, WIP compounds the formulation to order. Standard turnaround is typically several business days, though timelines vary by formulation complexity. Products are shipped directly to the patient or their provider.

Step 4: Ongoing Refills and Monitoring

Refills require a current prescription. Most states limit compounding prescriptions to a defined quantity without a new order from the prescriber. WIP does not perform hormone level testing, order labs, or conduct follow-up consultations. All clinical monitoring falls to the patient's external prescriber.

This four-step model places meaningful responsibility on the prescribing clinician. Patients who do not have an established hormone-specialist provider may find the model less convenient than integrated telehealth platforms that bundle prescribing, labs, and pharmacy services.

What Compounded BHRT Products Does Women's International Pharmacy Offer?

WIP compounds a wide range of hormone formulations. Common products include:

• Estradiol: creams, gels, troches, sublingual drops, vaginal suppositories, transdermal preparations
• Progesterone: oral capsules, creams, suppositories, troches
• Testosterone: creams, troches, injections (where permitted by state law)
• DHEA (dehydroepiandrosterone): capsules, creams, vaginal suppositories
• Estriol: vaginal creams, suppositories (commonly prescribed for genitourinary syndrome of menopause)
• Combination formulas: bi-est (estradiol plus estriol) and tri-est (estradiol, estriol, estrone) preparations

The Evidence Field for These Formulations

The clinical evidence for compounded BHRT varies substantially by formulation and route of delivery.

Estradiol and progesterone: Transdermal estradiol and oral micronized progesterone are supported by a substantial body of evidence. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) showed that low-dose transdermal estradiol and oral progesterone did not accelerate subclinical atherosclerosis over 48 months compared with placebo [3]. Oral micronized progesterone (Prometrium, 200 mg) is FDA-approved and carries the same molecular structure as endogenous progesterone, making it "bioidentical" by definition without requiring a compounding pharmacy.

Estriol: Estriol is not FDA-approved as a standalone drug in the United States. Compounded estriol preparations therefore fall outside the FDA-approved drug framework. The FDA sent warning letters to several compounding pharmacies in 2008 regarding estriol claims, noting that it is not a component of any FDA-approved drug [2]. Some evidence supports vaginal estriol for genitourinary symptoms, including a Cochrane review of vaginal estrogens that found benefit for recurrent urinary tract infections in postmenopausal women [4], but the evidence base is weaker than for estradiol.

Bi-est and Tri-est: No large randomized controlled trials have established the efficacy or safety of bi-est or tri-est combinations. The Endocrine Society's 2016 clinical practice guideline on menopausal hormone therapy stated that there is "no evidence that compounded bioidentical hormones are safer or more effective than approved hormone therapy" [5].

Testosterone for women: Off-label testosterone therapy for women has emerging support. A 2019 global consensus statement published in the journal Menopause concluded that testosterone therapy improves sexual function in postmenopausal women, though it noted a lack of long-term cardiovascular and breast safety data at doses producing physiologic female-range levels [6].

How Does Women's International Pharmacy Compare to Alternatives?

Patients seeking BHRT have several distinct categories of options. WIP occupies one specific niche within that field.

WIP vs. FDA-Approved Bioidentical Hormone Products

FDA-approved bioidentical products include estradiol patches (Vivelle-Dot, Climara, Minivelle), estradiol gels (Divigel, EstroGel), estradiol sprays (Evamist), vaginal estradiol rings (Femring, Estring), and oral micronized progesterone (Prometrium). These products have defined bioavailability data, pharmacokinetic profiles, and manufacturing controls validated through the FDA approval process.

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement notes that FDA-approved hormone therapies have a well-established benefit-risk profile for managing vasomotor symptoms in appropriate candidates [7]. Choosing a compounded alternative over an approved equivalent adds regulatory uncertainty without a demonstrated clinical benefit for most patients.

WIP vs. Telehealth BHRT Platforms

Integrated telehealth platforms such as Midi Health, Alloy, Gennev, and Evernow bundle prescriber consultations, lab coordination, and pharmacy fulfillment in a single service. A patient with no existing hormone prescriber may find these platforms faster and more convenient than working with WIP, which requires the patient to independently arrange prescriber and lab services.

The trade-off is customization. WIP can compound unusual dosage forms, strengths, or delivery routes that mass-market telehealth pharmacies do not stock. For patients with documented hypersensitivities to excipients in commercial products, or for providers who need a specific dose not available commercially, compounding has a genuine clinical role.

WIP vs. Other Compounding Pharmacies

Other PCAB-accredited compounding pharmacies serving similar patient populations include Belmar Pharmacy (Colorado), Help Pharmacy (Texas), and Strive Pharmacy (Arizona). Help holds both 503A and 503B designations, which allows it to produce larger batch quantities for certain products. Patients and prescribers should compare turnaround times, available formulations, shipping footprint (state licensing), and cost when choosing among these pharmacies.

What Does Women's International Pharmacy Cost?

WIP does not publish a public price list for compounded preparations. Costs depend on the specific hormone(s), dosage form, strength, and quantity prescribed.

As a general benchmark drawn from compounding pharmacy pricing norms:

• Compounded progesterone cream (30g, 100 mg/mL): typically $40 to $80 per month
• Compounded bi-est cream: typically $50 to $100 per month
• Compounded testosterone cream for women: typically $40 to $90 per month

Compounded preparations are generally not covered by commercial health insurance or Medicare Part D, because they are not FDA-approved drugs. Some patients with health savings accounts (HSAs) or flexible spending accounts (FSAs) may be able to use those funds, though this depends on the individual plan and whether the prescription meets IRS medical expense criteria.

Patients should request an itemized quote from WIP directly before initiating a prescription, since the pharmacy can provide cost information specific to the formulation prescribed.

What the Clinical Guidelines Actually Say About Compounded BHRT

Multiple major medical societies have published positions relevant to compounded BHRT that patients and prescribers should understand before choosing a compounding pharmacy over approved alternatives.

Endocrine Society

The Endocrine Society's 2016 guideline states directly: "We recommend against the use of compounded bioidentical hormones due to the lack of evidence for their safety and efficacy and the existence of FDA-approved bioidentical hormones for most standard indications." [5] The society acknowledged that compounding remains appropriate for patients with documented allergies to excipients in approved products or who need non-standard doses.

North American Menopause Society

NAMS's 2022 position statement notes that "custom-compounded hormones should not be considered risk-free and are not recommended for routine use when FDA-approved therapies are available." [7] The statement does recognize a limited role for compounding in specific clinical scenarios.

American College of Obstetricians and Gynecologists

ACOG's Committee Opinion on compounded bioidentical menopausal hormone therapy (most recently updated in 2022) cautions that "there is no scientific evidence to support claims of improved efficacy or safety for individualized compounded hormone therapy compared with conventional hormone therapy." [8]

These positions do not mean WIP is operating illegally or irresponsibly. They reflect a consensus that compounding should be a clinically justified exception rather than a default choice.

Salivary Hormone Testing and Dose Customization: A Critical Look

WIP and many prescribers who use compounding pharmacies rely on salivary hormone testing to guide BHRT dosing. Salivary testing is marketed as a way to "personalize" therapy.

The evidence does not support salivary testing as a reliable method for dosing hormone therapy. The Endocrine Society's position on hormone testing states that serum assays (blood tests) remain the standard for measuring estradiol, progesterone, and testosterone, and that salivary hormone measurements have poor correlation with serum levels and lack standardized reference ranges [5]. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that estradiol values from salivary assays varied by more than 300% across laboratories for identical samples [9].

Dose adjustments made on the basis of salivary results may therefore not reflect true circulating hormone levels. Patients receiving BHRT through any compounding pharmacy should ask their prescriber whether serum testing is being used to guide and monitor therapy.

Who Is Women's International Pharmacy Right For?

WIP may be a reasonable choice in a narrow set of clinical circumstances:

• Patients who already have an established hormone-prescribing provider and need a specific compounded formulation not available commercially.
• Patients with confirmed allergies or intolerances to excipients (dyes, preservatives, oils) in FDA-approved hormone products.
• Patients who need a dosage form not manufactured commercially, such as a vaginal suppository combining estriol and DHEA at a specific ratio.
• Providers who need a compounding partner with PCAB accreditation and a long operational track record.

WIP is a poor fit for patients who do not have an existing prescriber, who want integrated lab monitoring, or who are looking for the most evidence-backed hormone therapy option available. In those cases, starting with an FDA-approved bioidentical product through a standard pharmacy or an integrated telehealth platform is the more straightforward path.

Key Safety Considerations Before Starting Compounded BHRT

Hormone therapy of any kind carries a benefit-risk profile that depends on patient age, time since menopause onset, cardiovascular history, breast cancer risk, and other individual factors.

The Women's Health Initiative (WHI) Memory Study and the main WHI hormone trial established that combined estrogen-progestogen therapy in older postmenopausal women (mean age 63) increased breast cancer risk (hazard ratio 1.26 after 5.6 years) and did not reduce coronary heart disease [10]. Subsequent reanalysis and the KEEPS and ELITE trials have clarified that younger women initiating hormone therapy closer to menopause onset have a more favorable risk profile, a concept known as the "timing hypothesis."

None of this evidence comes from compounded formulations specifically. Because compounded preparations are not tested in large RCTs, their risk profiles are inferred from the pharmacology of the active ingredients rather than from direct outcome data.

Patients should discuss absolute and relative contraindications with their prescriber. These include a personal history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, and a history of thromboembolic events.

The NAMS 2022 statement is explicit: "The benefits of hormone therapy outweigh the risks for the majority of symptomatic women aged <60 years or who are within 10 years of menopause onset without contraindications." [7]